FDA warns Originitalia SRL over manufacturing quality failures in OTC drugs, including untested active ingredient and missing release testing.
What happened
FDA inspected the drug manufacturing facility from May 20 to 24, 2024. The inspection found that the firm did not test incoming active ingredient for identity, did not perform finished-product release testing, did not validate manufacturing and cleaning processes, and lacked adequate stability data. FDA reviewed the firm’s June 13, 2024 response and found it inadequate; the firm said it was freezing OTC production for 2024.
What FDA found
Failed to test each incoming active ingredient lot for identity and relied on supplier certificates without validating them.
21 CFR 211.84(d)(1) and 211.84(d)(2)Failed to test each finished drug batch for identity and strength before release.
21 CFR 211.165(a)Failed to validate manufacturing processes, show cleaning was adequate to prevent contamination, and qualify a system referenced in the letter.
21 CFR 211.100(a)Failed to have adequate stability data supporting storage conditions and expiration dates.
21 CFR 211.166(a)Did not operate an effective quality system; the quality unit was not enabled to exercise proper authority.
What FDA wants
Respond in writing within 15 working days with what you have done to correct the violations and prevent recurrence, and notify FDA before resuming drug manufacturing. FDA also recommends a qualified CGMP consultant if the firm intends to resume making drugs for the U.S. market.
Who should pay attention
- U.S. distributors and retailers of OTC drugs made by this firm
- brands or importers sourcing finished OTC drugs from Italian contract manufacturers
- companies relying on supplier certificates of analysis for incoming active ingredient
This is a summary. Read the original letter on fda.gov.